Rajen Mody1, Alice L Yu2,3, Arlene Naranjo4, Fan F Zhang5, Wendy B London6, Barry L Shulkin7, Marguerite T Parisi8, Sabah-E-Noor Servaes9, Mitchell B Diccianni2, Jacquelyn A Hank10, Mildred Felder10, Jennifer Birstler10, Paul M Sondel10, Shahab Asgharzadeh11, Julia Glade-Bender12, Howard Katzenstein13, John M Maris9, Julie R Park8, Rochelle Bagatell9. 1. C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI. 2. University of California San Diego, San Diego, CA. 3. Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taiwan. 4. Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL. 5. Children's Oncology Group Statistics and Data Center, Monrovia, CA. 6. Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. 7. St Jude Children's Research Hospital and University of Tennessee Health Science Center, Memphis, TN. 8. Seattle Children's Hospital and University of Washington, Seattle, WA. 9. Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA. 10. University of Wisconsin, Madison, WI. 11. Children's Hospital of Los Angeles and University of Southern California, Los Angeles, CA. 12. Memorial Sloan Kettering Cancer Center, New York, NY. 13. Nemour's Children's Clinic, Jacksonville, FL.
Abstract
PURPOSE: The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children's Oncology Group ANBL1221 trial. To more accurately assess response rate and toxicity, an expanded cohort was nonrandomly assigned to I/T/DIN/GM-CSF. PATIENTS AND METHODS: Patients were eligible at first relapse or first designation of refractory disease. Oral T and intravenous (IV) irinotecan were administered on days 1 to 5 of 21-day cycles. DIN was administered IV (days 2-5), and GM-CSF was administered subcutaneously (days 6-12). The primary end point was objective response, analyzed on an intent-to-treat basis per the International Neuroblastoma Response Criteria. RESULTS:Seventeen eligible patients were randomly assigned to I/T/DIN/GM-CSF (February 2013 to March 2015); 36 additional patients were nonrandomly assigned to I/T/DIN/GM-CSF (August 2016 to May 2017). Objective (complete or partial) responses were observed in nine (52.9%) of 17 randomly assigned patients (95% CI, 29.2% to 76.7%) and 13 (36.1%) of 36 expansion patients (95% CI, 20.4% to 51.8%). Objective responses were seen in 22 (41.5%) of 53 patients overall (95% CI, 28.2% to 54.8%); stable disease was also observed in 22 of 53. One-year progression-free and overall survival for all patients receiving I/T/DIN/GM-CSF were 67.9% ± 6.4% (95% CI, 55.4% to 80.5%) and 84.9% ± 4.9% (95% CI, 75.3% to 94.6%), respectively. Two patients did not receive protocol therapy and were evaluable for response but not toxicity. Common grade ≥ 3 toxicities were fever/infection (18 [35.3%] of 51), neutropenia (17 [33.3%] of 51), pain (15 [29.4%] of 51), and diarrhea (10 [19.6%] of 51). One patient met protocol-defined criteria for unacceptable toxicity (grade 4 hypoxia). Higher DIN trough levels were associated with response. CONCLUSION: I/T/DIN/GM-CSF has significant antitumor activity in patients with relapsed/refractory neuroblastoma. Study of chemoimmunotherapy in the frontline setting is indicated, as is further evaluation of predictive biomarkers.
RCT Entities:
PURPOSE: The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children's Oncology Group ANBL1221 trial. To more accurately assess response rate and toxicity, an expanded cohort was nonrandomly assigned to I/T/DIN/GM-CSF. PATIENTS AND METHODS: Patients were eligible at first relapse or first designation of refractory disease. Oral T and intravenous (IV) irinotecan were administered on days 1 to 5 of 21-day cycles. DIN was administered IV (days 2-5), and GM-CSF was administered subcutaneously (days 6-12). The primary end point was objective response, analyzed on an intent-to-treat basis per the International Neuroblastoma Response Criteria. RESULTS: Seventeen eligible patients were randomly assigned to I/T/DIN/GM-CSF (February 2013 to March 2015); 36 additional patients were nonrandomly assigned to I/T/DIN/GM-CSF (August 2016 to May 2017). Objective (complete or partial) responses were observed in nine (52.9%) of 17 randomly assigned patients (95% CI, 29.2% to 76.7%) and 13 (36.1%) of 36 expansion patients (95% CI, 20.4% to 51.8%). Objective responses were seen in 22 (41.5%) of 53 patients overall (95% CI, 28.2% to 54.8%); stable disease was also observed in 22 of 53. One-year progression-free and overall survival for all patients receiving I/T/DIN/GM-CSF were 67.9% ± 6.4% (95% CI, 55.4% to 80.5%) and 84.9% ± 4.9% (95% CI, 75.3% to 94.6%), respectively. Two patients did not receive protocol therapy and were evaluable for response but not toxicity. Common grade ≥ 3 toxicities were fever/infection (18 [35.3%] of 51), neutropenia (17 [33.3%] of 51), pain (15 [29.4%] of 51), and diarrhea (10 [19.6%] of 51). One patient met protocol-defined criteria for unacceptable toxicity (grade 4 hypoxia). Higher DIN trough levels were associated with response. CONCLUSION: I/T/DIN/GM-CSF has significant antitumor activity in patients with relapsed/refractory neuroblastoma. Study of chemoimmunotherapy in the frontline setting is indicated, as is further evaluation of predictive biomarkers.
Authors: Rochelle Bagatell; Wendy B London; Lars M Wagner; Stephan D Voss; Clinton F Stewart; John M Maris; Cynthia Kretschmar; Susan L Cohn Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: Brian H Kushner; Irene Y Cheung; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Nai-Kong Cheung Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Jacquelyn A Hank; Jacek Gan; Hyunji Ryu; Amy Ostendorf; Michael C Stauder; Adam Sternberg; Mark Albertini; Kin-Ming Lo; Stephen D Gillies; Jens Eickhoff; Paul M Sondel Journal: Clin Cancer Res Date: 2009-09-08 Impact factor: 12.531
Authors: Sara M Federico; M Beth McCarville; Barry L Shulkin; Paul M Sondel; Jacquelyn A Hank; Paul Hutson; Michael Meagher; Aaron Shafer; Catherine Y Ng; Wing Leung; William E Janssen; Jianrong Wu; Shenghua Mao; Rachel C Brennan; Victor M Santana; Alberto S Pappo; Wayne L Furman Journal: Clin Cancer Res Date: 2017-09-22 Impact factor: 12.531
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Rosa Nguyen; Xiyuan Zhang; Ming Sun; Shahroze Abbas; Charlie Seibert; Michael C Kelly; Jack F Shern; Carol J Thiele Journal: Clin Cancer Res Date: 2022-09-01 Impact factor: 13.801
Authors: Shawn J Macha; Balakrishna Koneru; Trevor A Burrow; Charles Zhu; Dzmitry Savitski; Rakhshanda L Rahman; Catherine A Ronaghan; Jonas Nance; Kristyn McCoy; Cody Eslinger; C Patrick Reynolds Journal: Cancer Res Date: 2022-09-16 Impact factor: 13.312
Authors: Wayne L Furman; Beth McCarville; Barry L Shulkin; Andrew Davidoff; Matthew Krasin; Chia-Wei Hsu; Haitao Pan; Jianrong Wu; Rachel Brennan; Michael W Bishop; Sara Helmig; Elizabeth Stewart; Fariba Navid; Brandon Triplett; Victor Santana; Teresa Santiago; Jacquelyn A Hank; Stephen D Gillies; Alice Yu; Paul M Sondel; Wing H Leung; Alberto Pappo; Sara M Federico Journal: J Clin Oncol Date: 2021-12-06 Impact factor: 44.544
Authors: Sanam Shahid; Brian H Kushner; Shakeel Modak; Ellen M Basu; Elyssa M Rubin; Gunes Gundem; Elli Papaemmanuil; Stephen S Roberts Journal: Pediatr Blood Cancer Date: 2021-07-31 Impact factor: 3.838
Authors: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Arlene Naranjo; Mitchell B Diccianni; Jacek Gan; Jacquelyn A Hank; Ayse Batova; Wendy B London; Sheena C Tenney; Malcolm Smith; Barry L Shulkin; Marguerite Parisi; Katherine K Matthay; Susan L Cohn; John M Maris; Rochelle Bagatell; Julie R Park; Paul M Sondel Journal: Clin Cancer Res Date: 2021-01-27 Impact factor: 13.801
Authors: Sara A Mansfield; M Beth McCarville; John T Lucas; Matthew J Krasin; Sara M Federico; Victor M Santana; Wayne L Furman; Andrew M Davidoff Journal: Ann Surg Oncol Date: 2021-07-02 Impact factor: 5.344
Authors: Steven G DuBois; M Meaghan Granger; Susan Groshen; Denice Tsao-Wei; Lingyun Ji; Anasheh Shamirian; Scarlett Czarnecki; Fariba Goodarzian; Rachel Berkovich; Hiroyuki Shimada; Judith G Villablanca; Kieuhoa T Vo; Navin Pinto; Yael P Mosse; John M Maris; Suzanne Shusterman; Susan L Cohn; Kelly C Goldsmith; Brian Weiss; Gregory A Yanik; Clare J Twist; Meredith S Irwin; Daphne A Haas-Kogan; Julie R Park; Araz Marachelian; Katherine K Matthay Journal: J Clin Oncol Date: 2021-07-16 Impact factor: 44.544
Authors: Riyue Bao; Stefani Spranger; Kyle Hernandez; Yuanyuan Zha; Peter Pytel; Jason J Luke; Thomas F Gajewski; Samuel L Volchenboum; Susan L Cohn; Ami V Desai Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751